Category: BioTech

FB Nasdaq FB Facebook
BioTech

Biotech Stocks Touching New Highs: Clovis Oncology (NASDAQ:CLVS), Vanda Pharmaceuticals (NASDAQ:VNDA), Insys Therapeutics (NASDAQ:INSY), Albany Molecular Research (NASDAQ:AMRI)

Clovis Oncology Inc. reported a fourth quarter loss of $0.92 per share after the bell Thursday, compared to the loss of $0.81 per share last year. Clovis Oncology Inc. (NASDAQ:CLVS) stock performance was 1.58% in last session and finished the day at $79.62. Traded volume was 0.00 shares in the last session and the average volume of the stock remained 589,825.00 shares. The beta of … Continue reading Biotech Stocks Touching New Highs: Clovis Oncology (NASDAQ:CLVS), Vanda Pharmaceuticals (NASDAQ:VNDA), Insys Therapeutics (NASDAQ:INSY), Albany Molecular Research (NASDAQ:AMRI)

Jason Knox
BioTech, Stock Movers

Array Biopharma (NASDAQ:ARRY) Jumping Pre-Bell, SolarCity (NASDAQ:SCTY), Nu Skin Enterprises (NYSE:NUS) Slip

Array BioPharma (NASDAQ:ARRY) was up more than 9% in pre-market trade after reporting positive study results for its asthma treatment. The company said, ARRY-502, an oral CRTh2 antagonist, was studied in a 184-patient placebo-controlled, randomized, double-blind Phase 2 trial in mild to moderate persistent allergic asthma, a population representing more than 12 million patients in the U.S. ARRY-502 met the primary endpoint in the trial, … Continue reading Array Biopharma (NASDAQ:ARRY) Jumping Pre-Bell, SolarCity (NASDAQ:SCTY), Nu Skin Enterprises (NYSE:NUS) Slip

John Meady
BioTech

Biotech Overbought Stocks: Agenus Inc. (NASDAQ:AGEN), Biota Pharmaceuticals (NASDAQ:BOTA), Albany Molecular Research (NASDAQ:AMRI), Sunesis Pharmaceuticals (NASDAQ:SNSS)

Agenus Inc. (NASDAQ:AGEN) will release its fourth quarter and year end 2013 financial results before the market opens on March 5, 2014. Agenus Inc. (NASDAQ:AGEN) stock performance was 0.00% in last session and finished the day at $4.89. Traded volume was 0.00 shares in the last session and the average volume of the stock remained 1.12 million shares. The beta of the stock remained 1.33. … Continue reading Biotech Overbought Stocks: Agenus Inc. (NASDAQ:AGEN), Biota Pharmaceuticals (NASDAQ:BOTA), Albany Molecular Research (NASDAQ:AMRI), Sunesis Pharmaceuticals (NASDAQ:SNSS)

Jayne Crisman
BioTech

Biotech Bearish Stocks: Questcor Pharmaceuticals (NASDAQ:QCOR), ACADIA Pharmaceuticals (NASDAQ:ACAD), Idera Pharmaceuticals (NASDAQ:IDRA), Celldex Therapeutics (NASDAQ:CLDX)

Citron exposes explosive findings behind the true components of Questcor Pharmaceuticals Inc (NASDAQ:QCOR) flagship drug HP Acthar Gel. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) stock performance was -9.96% in last session and finished the day at $60.75. Traded volume was 0.00 shares in the last session and the average volume of the stock remained 2.86 million shares. The beta of the stock remained 0.95. Questcor Pharmaceuticals Inc. … Continue reading Biotech Bearish Stocks: Questcor Pharmaceuticals (NASDAQ:QCOR), ACADIA Pharmaceuticals (NASDAQ:ACAD), Idera Pharmaceuticals (NASDAQ:IDRA), Celldex Therapeutics (NASDAQ:CLDX)

John Bellich
BioTech

Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Rexahn Pharmaceuticals (NYSEMKT:RNN), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -3.34% in last session and finished the day at $8.69. Traded volume was 1,200.00 shares in the last session and the average volume of the stock remained 26.48 million shares. The beta of the stock remained 1.64. Ariad Pharmaceuticals, Inc. … Continue reading Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Rexahn Pharmaceuticals (NYSEMKT:RNN), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Kevin Long
BioTech, Finance, news

Pharma in Focus: CLIR, CGEN, GALE

ClearSign Combustion Corporation (NASDAQ:CLIR) said it agreed to sell $6.5 million of its common stock to certain institutional investors at $8.00 each, a 9% discount to Thursday’s closing price. The company will sell 812,500 shares and will use the net proceeds for research and development, protection of intellectual property, business development and marketing, and for working capital. The company designs technology to improve the efficiency … Continue reading Pharma in Focus: CLIR, CGEN, GALE

John Meady